CNBX · XBRL financial data
CNBX Pharmaceuticals financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (CNBX's year ends in late August)
| In millions of dollars | Aug 31, 2023 | Nov 30, 2023 | Feb 29, 2024 | May 31, 2024 | Aug 31, 2024 | Nov 30, 2024 | Feb 28, 2025 | †May 31, 2025 | †Aug 31, 2025 | Nov 30, 2025 | Feb 28, 2026 | May 31, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 |
| Cost of revenue | — | — | 0 | — | — | — | 0 | 0 | — | — | 0 | 0 |
| Gross profit | — | — | 0 | — | — | — | 0 | 0 | — | — | 0 | 0 |
| Research and development | 0* | 0 | 0 | 0 | (0)* | 0 | 0 | 0 | 0* | 0 | 0 | — |
| General and administrative | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 |
| Total operating expenses | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 |
| Operating income (loss) | (0)* | (0) | (0) | (0) | (0)* | (0) | (0) | (0) | (0)* | (0) | (0) | (0) |
| Interest expense | — | 0 | 0* | 0* | — | 0 | 0* | 0* | 0* | 0 | (0)* | — |
| Other income (expense) | 0* | (0) | 0 | 0 | 0* | 0 | (0) | (0) | 0* | (0) | 0 | 0 |
| Net income (loss) | (1)* | (0) | (0) | (0) | (0)* | (0) | (0) | (0) | (0)* | (0) | (0) | (0) |
| Earnings per share, basic USD per share | — | (0.00) | (0.01) | 0.00 | 0.00* | (0.00) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | — | (0.00) | (0.01) | 0.00 | 0.00* | (0.00) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Weighted average shares, basic millions of shares | — | 28 | 31 | 31 | 31* | 31 | 32 | 43 | — | 733 | 931 | 1,319 |
| Weighted average shares, diluted millions of shares | — | 28 | 31 | 31 | 31* | 31 | 32 | 43 | — | 733 | 931 | 1,319 |
- † Share count changed about 22x in the period ending 2025-05-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 6x in the period ending 2025-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (CNBX's year ends in late August)
| In millions of dollars | Aug 31, 2023 | Nov 30, 2023 | Feb 29, 2024 | May 31, 2024 | Aug 31, 2024 | Nov 30, 2024 | Feb 28, 2025 | †May 31, 2025 | †Aug 31, 2025 | Nov 30, 2025 | Feb 28, 2026 | May 31, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prepaid and other current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Property and equipment, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total current liabilities | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Accumulated deficit | (24) | (24) | (25) | (25) | (25) | (25) | (25) | (25) | (25) | (25) | (25) | (26) |
| Total stockholders' equity | (2) | (2) | (2) | (2) | (2) | (3) | (3) | (3) | (2) | (3) | (3) | (3) |
| Total liabilities and equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common shares outstanding (cover page) millions of shares | 28 | 31 | 31 | 31 | 31 | 31 | 4 | 93 | 554 | 871 | 1,226 | 1,606 |
- † Share count changed about 22x in the period ending 2025-05-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 6x in the period ending 2025-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (CNBX's year ends in late August)
| In millions of dollars | Aug 31, 2023 | Nov 30, 2023 | Feb 29, 2024 | May 31, 2024 | Aug 31, 2024 | Nov 30, 2024 | Feb 28, 2025 | †May 31, 2025 | †Aug 31, 2025 | Nov 30, 2025 | Feb 28, 2026 | May 31, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (1)* | (0) | (0) | (0) | (0)* | (0) | (0) | (0) | (0)* | (0) | (0) | (0) |
| Stock-based compensation | 0* | 0 | 0* | 0* | 0* | 0 | 0* | 0* | 0* | 0 | — | — |
| Net cash from operating activities | 0* | (0) | (0)* | 0* | (0)* | (0) | (0)* | (0)* | (0)* | (0) | (0)* | (0)* |
| Net cash from investing activities | 0* | (0) | 0* | 0* | 0* | 0 | 0* | 0* | 0* | 0 | — | — |
| Proceeds from issuing equity | — | 0 | — | — | — | 0 | — | — | — | — | — | — |
| Net cash from financing activities | 0* | 0 | 0* | 0* | 0* | 0 | 0* | 0* | 0* | 0 | 0* | 0* |
| Net change in cash | — | (0) | (0)* | 0* | — | (0) | 0* | (0)* | — | (0) | 0* | (0)* |
- † Share count changed about 22x in the period ending 2025-05-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 6x in the period ending 2025-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| CNBX Pharmaceuticals | 0 | 0 | (0)* | 1.6B | 0.2 quarters | 10-QMay 31, 2026 |
| Bioadaptives | 0 | 0 | (0)* | 196.9M | 0.7 quarters | 10-QJun 30, 2026 |
| Eloxx Pharmaceuticals | 62 | not reported | (4.8)* | 4.0M | 12.9 quarters | 10-QJun 30, 2026 |
| NovAccess Global | 0 | 0* | (0.1)* | 61.7M | 0.4 quarters | 10-KSep 30, 2024 |
| Avenue Therapeutics | 1.9 | 0 | (0.5)* | 3.3M | 4.1 quarters | 10-QJun 30, 2026 |
| Emmaus Life Sciences | 2.8 | 6.3 | 1.7* | 70.2M | — | 10-QJun 30, 2026 |
| International Stem Cell | 1.1 | 2.7 | 0.2* | 8.0M | — | 10-QJun 30, 2026 |
| Nutra Pharma | not reported | 0 | (0.3)* | 7.2B | 0.1 quarters | 10-QJun 30, 2026 |
| Mosaic ImmunoEngineering | 0 | not reported | (0)* | 7.2M | 0.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.